Menu Close

SVA on the Front Line of the rVSV-ZEBOV studies

Coordinated by the SVA, the VSV-EBOVAC project “Vaccine safety and immunogenicity signatures of human responses to rVSV-ZEBOV” brings together 12 leading international vaccine research institutes, both clinical and high tech, from 6 EU countries and USA, as well as two African clinical sites to acquire new and critical in-depth knowledge of innate and adaptive immune responses elicited in humans by rVSV-ZEBOV vaccine with special emphasis on transcriptomic and metabolomic signatures. 

Leave a Reply